Sign inJoin waitlistJoin the waitlist

Harry Paul Erba

Professor of Medicine · Duke Department of Medicine

Credentials: · · ·

History

Duke Department of Medicine
Present
Duke Cancer Institute
Present

Stanford University School of Medicine
1988

Research

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
New England Journal of Medicine · 2018 · 1,234 citations
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
New England Journal of Medicine · 2019 · 1,078 citations
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Blood · 2015 · 842 citations

Frederick Appelbaum
44 papers
MT
Martin Tallman
42 papers
Richard Stone
36 papers
Mark Litzow
31 papers
Jerald Radich
25 papers
Mikkael Sekeres
24 papers
Guillermo Garcia-Manero
20 papers
Richard Larson
20 papers
Roland Walter
20 papers
Anjali Advani
17 papers
EE
Elihu Estey
17 papers
Selina Luger
17 papers

Grants

The Duke University - Duke Cancer Institute National Clinical Trials Network LAPS (UG1) Support Grant
National Cancer Institute · UG1
PI · $2.6M · Duke University
2019–2026
NCTN Deep South Research Consortium
National Cancer Institute · U10
Contact PI · $995.6K · University of Alabama at Birmingham
2014–2019
General Clinical Research Center
National Center for Research Resources · M01
Project lead · $618 · University of Michigan at Ann Arbor
1998–2001
Comprehensive Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $714.7K · University of Alabama at Birmingham

Clinical trials

Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML
Principal investigator · Completed · Phase 2
Chroma Therapeutics
2009–2011
Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome
Study chair · Completed · Phase 2
University of Michigan Rogel Cancer Center
2000–2002
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2027
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2027